Our lead candidate, uproleselan, is in pivotal Phase 3 development for relapsed/refractory AML.

Uproleselan is an investigational first-in-class, E-selectin antagonist.

Uproleselan has received Breakthrough Therapy and Fast Track designations from the U.S. FDA for the treatment of adult AML patients with relapsed or refractory disease.